Halaven

Type: Product
Name: Halaven
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Eisai to present cancer drug data at ESMO 2014

:11 in Pharmaceutical Company Product News Eisai has announced that it will be presenting nine abstracts from its oncology portfolio at the 2014 European Society for Medical Oncology (ESMO) congress next week. The conference, which runs from September ... [Published Zenopa - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

New Halaven (Eribulin) and Lenvatinib Data to be Presented at ESMO 2014 Demonstrates Strength of Eisai Oncology Portfolio

/PRNewswire/ --FOR EMEA MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTSWealth of data highlights Eisai's commitment to people with cancer and their familiesNine abstracts for Eisai's oncology portfolio are to be presented during the European Society for Medical ... [Published FinanzNachrichten.de - Sep 17 2014]
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Forum Post: RE: Halaven (Eribulin)

I'm sorry you haven't had a reply to date. Perhaps you would be advised to contact one of the nurses here on this site. They operate Monday to Friday 9am to 8pm on FREEPHONE 0808 808 0000.Best wishesKateG ... [Published Macmillan Cancer Support - Aug 24 2014]
Entities: Eribulin, Halaven
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Forum Post: Halaven (Eribulin)

Hello,I've been on weekly Taxol/Avastin since my diagnosis of liver mets at the end of May. I had a CT scan after 2 cycles and they said there hasn't been any reduction in size of the main tumours, but some do the smaller ones had shrunk. However, my ... [Published Macmillan Cancer Support - Aug 22 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

HALAVEN (Eribulin Mesylate) Injection [Eisai Inc.]

First reported Aug 18 2014 - Updated Aug 18 2014 - 2 reports

Eisai files for US and EU approval of lenvatinib for hard to treat thyroid cancer

Japanese pharma major Eisai (TYO: 4523) has filed applications with the US Food and Drug Administration and the European Medicines Agency for the use of lenvatinib mesylate in the treatment of patients with progressive radioiodine-refractory differentiated ... [Published Pharma Letter - Aug 18 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 2 reports

No Overall Survival Benefit For Eisai’s Halaven In PhIII NSCLC Trial

Article # 28140814007Posted: Aug. 15, 2014 3:15 AM GMTExecutive SummaryProlongation of overall survival has not been achieved in an international Phase III trial with Eisai’s Halaven (eribulin mesylate) in the treatment of advanced non-small cell lung ... [Published Health News Daily - Aug 15 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 2 reports

Eisai gets EC approval of indication expansion for Halaven to treat breast cancer

Japanese pharmaceutical firm Eisai has received approval from the European Commission (EC) of the indication expansion of Halaven (eribulin mesylate) to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who ... [Published BioPortfolio - Jul 07 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Expanded EU approval sets Halaven on course

| SCRIPThe new indication means that it can be used in patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline ... [Published BioPortfolio - Jul 03 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Eisais breast cancer drug Halaven receives MAA in Europe

The European Commission has issued Marketing Authorization Approval (MAA) for Halaven (eribulin) from Japanese drug major Eisai in the treatment of patients with locally advanced or metastatic breast cancer (MBC) who have progressed after at least on ... [Published BioPortfolio - Jul 03 2014]
First reported May 27 2014 - Updated May 27 2014 - 2 reports

Eisai's Halaven Eribulin Receives Positive CHMP Opinion for Advanced Breast Cancer After Only One Prior Chemotherapy

/PRNewswire/ -- FOREUMEDIA ONLY: NOT FOR SWISSMEDIA New indicationtobenefitthousands of women across Europe The European Medicines Agency's (EMA) Committee for Medi...Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: Eisai's Halaven ... [Published BioPortfolio - May 27 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 2 reports

Eisai announces availability of Halaven in Lebanon for treatment of metastatic breast cancer

Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) has announces that Halaven (eribulin) is now commercially available in Lebanon as a treatment for women with locally advanced or metastatic breast cancer who have previously received at lea ... [Published BioPortfolio - Apr 07 2014]

Quotes

...Gary Hendler, president and chief executive officer for Eisai in Europe, said: "Eisai is committed to the provision of a range of options to help reduce the significant burden of cancer for patients, their families and healthcare systems." The company applied for EU and US regulatory approval of lenvatinib as a treatment for progressive radioiodine-refractory differentiated thyroid cancer...
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides" which we call human healthhealth care (hhc)
...still has significant unmet medical needs," said Kenichi Nomoto, PhD, President, Oncology Product Creation Unit, Eisai Product Creation Systems. "While eribulin did not show an improvement in OS compared to TPC in this study, the trial demonstrates that eribulin has anticancer activity in advanced NSCLC patients following at least two prior regimens and further analyses of the results are ongoing. These results do not affect the current approved indications for Halaven."
Original Article: NEXT ARTICLE More From BioPortfolio on "No Overall Survival Benefit For Eisai’s Halaven In PhIII NSCLC Trial"

More Content

All (29) | News (23) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Lebanon Pharmaceuticals & Healthcare Report Q4 ... [Published Digital Journal - Sep 18 2014]
Eisai to present cancer drug data at ESMO 2014 [Published Zenopa - Sep 18 2014]
New Halaven (Eribulin) and Lenvatinib Data to b... [Published FinanzNachrichten.de - Sep 17 2014]
Eribulin plus trastuzumab safe, effective in HE... [Published Orthopedics Today - Sep 10 2014]
Eisai's Phase III lung cancer study fails to me... [Published Individual.com - Aug 25 2014]
Forum Post: RE: Halaven (Eribulin) [Published Macmillan Cancer Support - Aug 24 2014]
Forum Post: Halaven (Eribulin) [Published Macmillan Cancer Support - Aug 22 2014]
HALAVEN (Eribulin Mesylate) Injection [Eisai Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Eisai files for US and EU approval of lenvatini... [Published Pharma Letter - Aug 18 2014]
Eisai applies for regulatory approval of new th... [Published Zenopa - Aug 18 2014]
Circulating Tumor Cells in Metastatic Breast Ca... [Published The ASCO Post - Aug 15 2014]
No Overall Survival Benefit For Eisai’s Halaven... [Published Health News Daily - Aug 15 2014]
No Overall Survival Benefit For Eisai’s Halaven... [Published BioPortfolio - Aug 15 2014]
Eisai gets EC approval of indication expansion ... [Published BioPortfolio - Jul 07 2014]
Eisai gets EC approval of indication expansion ... [Published PBR - News - Jul 07 2014]
Expanded EU approval sets Halaven on course [Published BioPortfolio - Jul 03 2014]
Eisais breast cancer drug Halaven receives MAA ... [Published BioPortfolio - Jul 03 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jun 12 2014]
Eisai's Halaven Eribulin Receives Positive CHMP... [Published BioPortfolio - May 27 2014]
Eisai Receives Positive Opinion from EMA's CHMP... [Published BioPortfolio - May 27 2014]
Pending EC decision: Halaven, eribulin, Opinion... [Published Pending EC decisions and European Public Assess ... - May 23 2014]
Eisai announces availability of Halaven in Leba... [Published BioPortfolio - Apr 07 2014]
Eisai announces availability of Halaven in Leba... [Published PBR - News - Apr 07 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 07 2014]
Eisai's lenvatinib to follow in Nexavar's foots... [Published BioPortfolio - Feb 04 2014]
The Pixie Awards Announces 2014 Competition Win... [Published PRWeb - Jan 23 2014]
Halaven Plus Herceptin Winning Combo CMECE [Published BioPortfolio - Dec 16 2013]
Eisai Oncology to Present Data Analyses on Hala... [Published BioPortfolio - Dec 05 2013]
Eisai to Present New Research on Halaven Eribul... [Published BioPortfolio - Dec 05 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
HALAVEN (Eribulin Mesylate) Injection [Eisai Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Updated Date: Aug 15, 2014 EST ...
Eisai gets EC approval of indication expansion ... [Published PBR - News - Jul 07 2014]
Japanese pharmaceutical firm Eisai has received approval from the European Commission (EC) of the indication expansion of Halaven (eribulin mesylate) to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jun 12 2014]
Pending EC decision: Halaven, eribulin, Opinion... [Published Pending EC decisions and European Public Assess ... - May 23 2014]
Eisai announces availability of Halaven in Leba... [Published PBR - News - Apr 07 2014]
Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) has announces that Halaven (eribulin) is now commercially available in Lebanon as a treatment for women with locally advanced or metastatic breast cancer who have previously received at least ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.